Abstract
BackgroundCytochrome P450 2J2 is mostly expressed in extrahepatic tissues; it metabolizes arachidonic acid to epoxyeicosatrienoic acids, with various cardio protective and anti-inflammatory effects. CYP2J2 polymorphism has been identified as a risk factor for cardiovascular diseases, but its association with psoriasis remains unknown. ObjectiveTo evaluate CYP2J2 polymorphism as a risk factor for psoriasis in the Turkish population. MethodsThere were 94 patients with psoriasis and 100 age- and sex-matched healthy controls included in the study. Detailed demographic and clinical characteristics were recorded, and Psoriasis Area and Severity Index (PASI) scores were calculated for psoriasis patients. Venous blood samples were collected from all the participants and CYP2J2 50G>T (rs890293) polymorphism was analyzed using polymerase chain reaction (PCR). ResultsBoth T allele and TT+GT genotype frequencies were increased in psoriasis vulgaris patients compared to the control group (p=0.024 and p=0.029 respectively, OR=2.82, 95% CI: 1.11–7.15) No association between CYP2J2 polymorphism and clinical features of psoriasis was identified. Study limitationsA limited number of patients were included in the study. ConclusionCYP2J2 50G>T (rs890293) polymorphism was associated with an increased risk for PsV in the Turkish population.
Highlights
Psoriasis is a chronic inflammatory skin disease characterized by sharply demarcated erythematous papules and plaques with silvery scales
Arthralgia was identified in 47% of psoriasis patients and 23% of patients were diagnosed with psoriatic arthritis
This study investigated the possible role of CYP2J2 polymorphism as a risk factor in psoriasis patients
Summary
Psoriasis is a chronic inflammatory skin disease characterized by sharply demarcated erythematous papules and plaques with silvery scales. The prevalence varies widely between studies (0---11.8%) according to age, gender, and race; psoriasis is thought to affect about 2% of the general population.[1] Psoriasis affects men and women . It can start at any age, two age peaks in the incidence have been observed: the first in second and third decade, and the second in fifth and sixth decade.[2] Skin, nail, or joint involvement can be seen in up to 50% of the patients, and the association of psoriasis with many systemic disorders such as cardiovascular diseases, infections, metabolic disorders, kidney diseases, gastrointestinal diseases, and malignancies is well documented.3---5. Many studies investigating systemic inflammation in psoriasis revealed that markers of inflammation (especially C-reactive protein, tumor necrosis factor [TNF]-␣, intracellular adhesion molecule [ICAM]-1, E-selectin, and interleukin [IL]-1, IL-6, IL-10) are increased in psoriatic patients, creating a systemic inflammatory state that could lead to comorbidities like cardiovascular diseases.[7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
